New drug brensocatib offered to bronchiectasis patients who completed key trial
NCT ID NCT05344508
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study provides early access to brensocatib, an experimental tablet, for people with non-cystic fibrosis bronchiectasis who finished the ASPEN trial. Participants must have already taken brensocatib without serious side effects. The goal is to offer continued treatment while more data is gathered.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Brensocatib tablets
- What this could lead to
- If successful, this could provide a new treatment option to control symptoms and reduce flare-ups in people with non-CF bronchiectasis.
- What could go wrong
- This is an early-access study, not a large trial. It only includes patients who already tolerated brensocatib, so results may not apply to everyone. Side effects are still possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-CYSTIC FIBROSIS BRONCHIECTASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A vibrating vest may help children with damaged lungs breathe easier
- Can a new biologic drug delay dangerous lung Flare-Ups?
- Inhaled experimental drug targets tough lung infections
- New drug trial aims to tame chronic lung infections
- Scientists develop risk score to forecast bronchiectasis attacks
- 500 patients to test if daily azithromycin keeps bronchiectasis attacks at bay